Form D · Pharmaceuticals
Can-Fite BioPharma Ltd.
Ramat Gan, L3 · CIK 0001536196
Offering snapshot reported Sep 10, 2026 · SEC filing
- Reported sold
- $8.31M Offering amount: $8.31M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 2, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 10, 2026 | Initial | $8,306,884 | No comparison | 1 | SEC filing |
| Dec 30, 2021 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Aug 26, 2021 | Initial | $9,996,900 | No comparison | Not reported | SEC filing |
| Jul 17, 2020 | Initial | $3,411,000 | No comparison | 3 | SEC filing |
| Jun 19, 2020 | Initial | $8,000,002 | No comparison | 4 | SEC filing |
| Jan 24, 2020 | Initial | $2,400,000 | No comparison | 4 | SEC filing |
| May 31, 2019 | Initial | $6,000,000 | No comparison | 5 | SEC filing |
| Apr 11, 2019 | Initial | $3,200,000 | No comparison | 2 | SEC filing |
| Jan 24, 2019 | Initial | $2,350,000 | No comparison | 1 | SEC filing |
| Mar 22, 2018 | Initial | $5,000,004 | No comparison | 3 | SEC filing |
| Jan 25, 2017 | Initial | $5,000,000 | No comparison | 8 | SEC filing |
| Oct 28, 2015 | Initial | $4,825,002 | No comparison | 3 | SEC filing |
| Oct 2, 2015 | Initial | $9,000,002 | No comparison | 3 | SEC filing |
| Dec 17, 2014 | Initial | $8,000,000 | No comparison | 4 | SEC filing |
| Mar 24, 2014 | Initial | $5,059,072 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $279K
- Finders' fees
- $0
- Form D file number
- 021-597072
Form D covers wts issued 9/3/26: investor wts (3,183,476 @ $2.50/share) and PA wts (111,422 at $3.125/share). Excludes exercise of warrants issued March 2026. Total offering amount equals exercise price of new wts if exercised in full.
7% cash fee + 1% mgmt. fee to HCW on warrant exercise proceeds. In addition, $25,000 for non-accountable expenses and $50,000 for accountable expenses. HCW agent warrants included in Item 13.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Sep 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yechezkel Barenholz | Director |
| Golan Bitton | Director |
| Yoseph Borenstein | Director |
| Yossi Bornstein | Director |
| Yoseph Bornstein | Director |
| Ilan Cohn | Director |
| Motti Farbstein | Executive |
| Pnina Fishman | Executive |
| Sari Fishman | Executive |
| Yaacov Goldman | Director |
| Gil Oren | Director |
| Guy Regev | Director |
| Abraham Sartani | Director |
| Abraham Sartini | Director |
| Israel Shamay | Director |
| Barak Singer | Director |
| Ilan Tamir | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
26 Ben Gurion Street
Ramat Gan, L3, 5257346
Phone: +972 (3) 924-1114
Ramat Gan, L3, 5257346
Phone: +972 (3) 924-1114